Table 1.
Characteristics of the study population (n = 50) including demographic data, clinical presentations, adverse events, and laboratory findings of snakebite patients.
| Variable | Description |
|---|---|
| Age, median (IQR) | 28.5 (15.25) |
| SSS, mean ± SD | 6.54 ± 3.39 |
| Antivenom dose, median (IQR) | 25 (15–35) |
| Length of stay, median (IQR) | 2 (2–3) |
| ICU admission, n (%) | 11 (22) |
| Duration of ICU admission, median (IQR) | 2 (1–2) |
| Signs, n (%) | |
| Edema | 47 (94) |
| Ecchymosis | 43 (86) |
| Blister | 35 (70) |
| Adverse events, n (%) | |
| GI | 9 (18) |
| Respiratory distress | 4 (8) |
| Cardiovascular | 2 (4) |
| Neurologic | 3 (6) |
| Lab data, n (%) | |
| Thrombocytopenia | 8 (16) |
| High serum Cr | 5 (10) |
| K disturbance | 6 (12) |
| Na disturbance | 3 (6) |
| Ca disturbance | 4 (8) |
| Abnormal PT | 11 (22) |
| Abnormal PTT | 5 (10) |
| Abnormal INR | 10 (20) |
| Abnormal BT | 3 (6) |
Abbreviations: BT, bleeding time; Cr, creatinine; GI, gastrointestinal; PT, prothrombin time; PTT, partial thromboplastin time; SSS, snakebite severity score.